skip to Main Content

Medicare (CMS) July 22nd 2018 Local Coverage Determination (LCD) Updates

Medicare (CMS) July 22nd 2018 Local Coverage Determination (LCD) Updates
Centers for Medicare & Medicaid Services (CMS) Local Coverage Determination (LCD) Updates

Centers for Medicare & Medicaid Services (CMS) Local Coverage Determination (LCD) Updates »

July 22nd Medicare (CMS) 2018 LCD Updates:

  • L33416                   3D Interpretation and Reporting of Imaging Studies
  • L35041                   Application of Bioengineered Skin Substitutes to Lower Extremity Chronic Non-Healing Wounds
  • A54117                  Application of Bioengineered Skin Substitutes to Lower Extremity Chronic Non-Healing Wounds
  • L35124                   Autonomic Function Testing
  • A55947 (retired)      Billing and Coding Guidance for Anti-Inhibitor Coagulant Complex (AICC) National Coverage Determination (NCD) 110.3
  • A56065                  Billing and Coding Guidance for Anti-Inhibitor Coagulant Complex (AICC) National Coverage Determination (NCD) 110.3
  • A55035                  Billing Requirements for Application of Skin Substitutes (Part B Services Only)
  • L35396                   Biomarkers for Oncology
  • A52986                  Biomarkers for Oncology
  • A55639                  Chemotherapy Agents for Non-Oncologic Conditions
  • L37205                   Chemotherapy Drugs and their Adjuncts
  • L33459                   Computerized Axial Tomography (CT), Thorax
  • L37697                   Emergency and Non-Emergency Ground Ambulance Services
  • A56070                  Emergency and non-emergency ground ambulance services revision to the Part A and Part B LCD
  • L34633                   Erythropoiesis Stimulating Agents (ESAs)
  • L34651                   Flow Cytometry
  • A56019                  High Intensity Focused Ultrasound (HIFU) in the Treatment of Recurrent Prostate Cancer
  • L34554                   In Vitro Chemosensitivity & Chemoresistance Assays
  • L34554                   In Vitro Chemosensitivity & Chemoresistance Assays
  • L35093                   Intravenous Immune Globulin (IVIG)
  • L34580                   Intravenous Immunoglobulin (IVIG)
  • A52930 (retired)      Jurisdiction F Medicare Part B LCD Notification
  • L36109                   Minimally Invasive Treatment for Benign Prostatic Hyperplasia Involving Prostatic Urethral Lift (Urolift®)
  • A54186                  MolDX: AlloMap Billing and Coding Guidelines Update
  • A55248                  MolDX: Approved Gene Testing
  • A55235                  MolDX: Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy (ARVD/C) Testing Coding and Billing Guidelines
  • L35631                   MolDX: Breast Cancer Index? Genetic Assay
  • L35868                   MolDX: Decipher® Prostate Cancer Classifier Assay
  • L35024                   MolDX: Genetic Testing for Lynch Syndrome
  • L35025                   MolDX: Molecular Diagnostic Tests (MDT)
  • L36807                   MolDX: Molecular Diagnostic Tests (MDT)
  • A55197                  MolDX: Next Generation Sequencing Coding and Billing Guidelines
  • A55198                  MolDX: NSD1 Gene Tests Coding and Billing Guidelines
  • A55230                  MolDX: Oncotype DX® Breast Cancer Assay Billing and Coding Guidelines
  • A55199                  MolDX: PAX6 Gene Sequencing Coding and Billing Guidelines
  • A55200                  MolDX: PIK3CA Gene Tests Coding and Billing Guidelines
  • A55203                  MolDX: PTCH1 Gene Testing Coding and Billing Guidelines
  • A55204                  MolDx: ResponseDX Tissue of Origin® Coding and Billing Guidelines
  • A55207                  MolDX: SLCO1B1 Genotype Coding and Billing Guidelines
  • A55208                  MolDX: SMPD1 Genetic Testing Coding and Billing Guidelines
  • A55211                  MolDX: TERC Gene Tests Coding and Billing Guidelines
  • A55846                  MolDX: ThermoFisher Oncomine Dx Target Test For Non-Small Cell Lung Cancer, Coding and Billing Guidelines
  • A55851                  MolDX: ThermoFisher Oncomine Dx Target Test For Non-Small Cell Lung Cancer, Coding and Billing Guidelines
  • A55911 (retired)      MolDX: ThermoFisher Oncomine Dx Target Test For Non-Small Cell Lung Cancer, Coding and Billing Guidelines
  • A55223                  MolDX: Vectra™ DA Coding and Billing Guidelines
  • L35753                   Non-Invasive Cerebrovascular Studies
  • A55640                  Not Otherwise Classified Chemotherapy Agents (NOC)
  • L37682                   Nusinersen (Spinraza)
  • A56062                  Percutaneous Electrical Nerve Stimulation (PENS) and Percutaneous Neuromodulation Therapy (PNT)
  • A52436                  Psychological Services Coverage under the Incident to Provision for Physicians and Non-physicians – Supplemental Instructions Article
  • L33444                   Pulmonary Stress Testing
  • A56068                  Response to Comments: MolDX: Breast Cancer IndexSM Genetic Assay
  • A56069                  Response to Comments: MolDX: Decipher® Prostate Cancer Classifier Assay
  • A55995                  Response to Comments: MolDX: In Vitro Chemosensitivity & Chemoresistance Assays
  • A56058                  Response to Comments: Nusinersen (Spinraza)
  • L35986                   Special Histochemical Stains and Immunohistochemical Stains
  • A55762                  Special Stains and Immunohistochemistry (IHC) Indications for Gastric Pathology
  • A52727 (retired)      STRATIFY JCV™ Coding and Billing Guidelines
  • A52868                  Transesophageal Echocardiography (TEE) – Supplemental Instructions Article
  • L34243                   Treatment of Ulcers & Symptomatic Hyperkeratoses
  • L33762                   Treatment of varicose veins of the lower extremity
  • A56064                  Treatment of varicose veins of the lower extremity revision to the Part A and Part B LCD
  • A52470                  Venipuncture Necessitating Physician’s Skill for Specimen Collection – Supplemental Instructions Article

 

Centers for Medicare & Medicaid Services (CMS) Local Coverage Determination (LCD) Updates »

 

Policy Alerts monitors Commercial and Medicare medical policies for changes. While medical Insurance carriers typically update medical policies annually, there are many reasons why they might review or update a policy. When reviews occur out of cycle they often go unnoticed. Policy Alerts keeps you updated when Payers make coverage changes to medical policies affecting your business.

Policy Alerts continuously monitors Commercial and Medicare Payer coverage information to keep you up-to-date on medical Insurance decisions in real-time. When changes occur, instant email alerts are delivered to your inbox. Clients have access to detailed coverage reports and medical policies through the interactive Policy Alerts Dashboard portal. Save time each month and keep focused on important Payer medical policy reviews and coverage decisions affecting your business!

Policy Alerts takes a client-focused hands-on approach and is constantly working to provide our customers with helpful insights and actionable analytics. We understand what our clients need and are dedicated to providing timely, accurate, and always up-to-date reports.

Health economic and reimbursement information provided by Policy Alerts is gathered from third-party sources and is subject to change without notice as a result of complex and frequently changing laws, regulations, rules and policies. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them. This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice.

Back To Top